A New Approach to Repurposing: Ditch the Hypotheses

By pulling together 35 publicly available gold-standard animal models, Melior Discovery has built a stable of what it calls privileged compounds. The repurposing company augments its VC funds with service deals and is aiming to progress its lead compound into Phase I studies in 2007.

Melior Discovery Inc., an 18-month old repurposing start-up in the Philadelphia suburbs, isn’t your typical biotech. The firm has no proprietary technology, hasn’t in-licensed any compounds, doesn’t boast an in-depth knowledge of specific biological targets or families of targets, and doesn’t keep an eagle eye on the latest advances in the literature to build its hypotheses about which compounds may succeed at treating which diseases. In fact, says Melior president and CEO Andrew Reaume, PhD, "ours isn’t a hypothesis-driven approach at all, and we don’t rely on linkages or disease associates or gene expression changes," he says. "We don’t do that kind of detective work."

But what Melior does do has attracted a small handful of pharmaceutical partners, including Merck & Co. Inc. , and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.